TY  - JOUR
AU  - Romero-Laorden, Nuria
AU  - Lozano, Rebeca
AU  - Jayaram, Anuradha
AU  - López-Campos, Fernando
AU  - Saez, Maria I
AU  - Montesa, Alvaro
AU  - Gutierrez-Pecharoman, Ana
AU  - Villatoro, Rosa
AU  - Herrera, Bernardo
AU  - Correa, Raquel
AU  - Rosero, Adriana
AU  - Pacheco, María I
AU  - Garcés, Teresa
AU  - Cendón, Ylenia
AU  - Nombela, Ma Paz
AU  - Van de Poll, Floortje
AU  - Grau, Gala
AU  - Rivera, Leticia
AU  - López, Pedro P
AU  - Cruz, Juan-Jesús
AU  - Lorente, David
AU  - Attard, Gerhardt
AU  - Castro, Elena
AU  - Olmos, David
PY  - 2018
DO  - 10.1038/s41416-018-0123-9
UR  - http://hdl.handle.net/10668/12862
T2  - British journal of cancer
AB  - Despite most metastatic castration-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs. Long-term use of prednisone has been suggested as one of the mechanisms...
LA  - en
KW  - Aged
KW  - Aged, 80 and over
KW  - Androstenes
KW  - Antineoplastic Agents, Hormonal
KW  - Dexamethasone
KW  - Disease Progression
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Oncogene Proteins, Fusion
KW  - PTEN Phosphohydrolase
KW  - Pilot Projects
KW  - Prednisone
KW  - Prospective Studies
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Receptors, Androgen
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
TY  - research article
VL  - 119
ER  -